Why is the comparison with Medicare for VOQUEZNA TRIPLE PAK labelled estimated?

Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Voquezna Triple Pak / Vonoprazan/Amoxicillin/Clarith: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.

Why does this page start at 1 unit (EA)?

NADAC prices this product per EA, and the FDA NDC Directory lists 1 of its 2 NDCs (it does not list the other one) as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and this is not one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.

VOQUEZNA TRIPLE PAK

FDA nonproprietary name: vonoprazan fumarate, amoxicillin and clarithromycin

For 1 unit (EA)

Pharmacies pay

$7.52 filed

1 × $7.5155 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$6.97 filed

1 × $6.96525 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

The spread

0.93× estimated

Medicare paid 7% less than pharmacies pay.

Part D averages every strength and form sold under “Voquezna Triple Pak” / “Vonoprazan/Amoxicillin/Clarith” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$13.65 estimated

$7.52 + $1.13 (15%) + $5.00 fee per fill = $13.65

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

VOQUEZNA TRIPLE PAK is how the CMS NADAC file names this product. The FDA NDC Directory lists it as vonoprazan fumarate, amoxicillin and clarithromycin, under the trade name “VOQUEZNA TRIPLE PAK”.

FDA gives its dosage form as kit.

The labeler, the company named on the label, is Phathom Pharmaceuticals Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $7.52 for 1 unit (EA) (1 × $7.5155 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · NADAC explanation codes

All 2 NDCs

81520-0255-01 · not listed as a package in the FDA directory · $7.5155 per EA · eff. 2026-09-23 filed
81520-0255-14 · Phathom Pharmaceuticals Inc. · $7.5155 per EA · eff. 2026-09-23 filed

What Medicare paid

Medicare Part D paid $6.97 for 1 unit (EA), at an average of $6.96525 per EA in 2024 (2024-01-01 to 2024-12-31) for “Voquezna Triple Pak” and “Vonoprazan/Amoxicillin/Clarith”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 317 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.

Questions

Why is the comparison with Medicare for VOQUEZNA TRIPLE PAK labelled estimated?: Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Voquezna Triple Pak / Vonoprazan/Amoxicillin/Clarith: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
Why does this page start at 1 unit (EA)?: NADAC prices this product per EA, and the FDA NDC Directory lists 1 of its 2 NDCs (it does not list the other one) as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and this is not one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.